MMED Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MiniMed Group Inc (MMED) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock is currently undervalued, with strong analyst support, a favorable risk/reward profile, and significant growth potential in the diabetes technology market. While technical indicators are mixed, the long-term growth prospects and positive analyst sentiment outweigh short-term concerns.
The technical indicators are mixed. The MACD histogram is negative (-0.477), suggesting bearish momentum, but it is contracting. RSI is neutral at 42.75, indicating no clear overbought or oversold condition. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading near a key support level (S1: 13.151). The pre-market price is $13.63, slightly above the support level but below the pivot point of 14.262.
Strong analyst ratings: Multiple analysts have initiated coverage with Buy or Overweight ratings and price targets ranging from $19 to $67, indicating significant upside potential.
Favorable market positioning: MiniMed is a 'full-stack' diabetes technology company with a differentiated product portfolio targeting a rapidly growing $18B market.
Growth potential: Analysts expect revenue to grow from under $100M in FY26 to nearly $400M annually by FY30, driven by product innovation and market penetration.
Technical weakness: Bearish moving averages and a lack of clear bullish momentum in technical indicators.
Competitive risks: Piper Sandler highlighted concerns about MiniMed's lagging form factor and ease-of-use compared to competitors, which could impact growth.
Financial performance: While revenue grew 10.26% YoY in Q2 2026, EPS dropped to -0.1, reflecting ongoing profitability challenges.
In Q2 2026, MiniMed's revenue increased by 10.26% YoY to $752M, and gross margin improved slightly to 57.05%. However, net income remained at 0, and EPS declined by 9.09% YoY to -0.1, indicating profitability challenges despite revenue growth.
Analyst sentiment is overwhelmingly positive, with multiple firms initiating coverage with Buy or Overweight ratings. Price targets range from $16 to $67, with most analysts highlighting the company's strong growth potential, differentiated product portfolio, and undervaluation at current levels. However, Piper Sandler expressed concerns about competitive positioning and growth risks.
